China has also joined the COVID-19 Vaccines Global Access (COVAX) facility, an effort led by the World Health Organization (WHO) and the global Coalition for Epidemic Preparedness Innovations (CEPI) to make sure that any products are proven to be safe and effective and quickly reach rich and poor countries alike.

@18K...u memamg lawak....hahahaha...

Ayam goreng kampung...tambah nasi nanti.

Yupe..let the sharks do what they want. Sooner or later they need to uplift prices. They cannot be holding down forever. I can wait.

Investing in share market is like selecting your wife. You choose the best from your girlfriends. After that you do not complain, explain or compare who is the best, if not you will not be happy. Hahahahaha....

I am beginning to see see antivax here just like what KJ was talking about....hahahaha..

I dare. If ruler of UAE dare take who is me not to take?

@UlarSawa..I just pandai pandai beli and tidur. Hahahaha..

Shark make money from people like me...correct....tak bagi umpan, mana dapat ikan? Pandai pandai lah tarik.

Shark come or no come no difference. When vaccine news is good and prices good, shark also want to make money, correct?

PUTRAJAYA, Dec 2 — Malaysia will closely monitor the deployment of the Covid-19 vaccine in the United Kingdom, following reports of Pfizer-BioNTech’s approval for its vaccine to be used among the public and healthcare workers there by next week.

Health director-general Tan Sri Dr Noor Hisham Abdullah said the ministry intends to monitor the developing situation there, to determine the vaccine's effectiveness and the emergency of any potential side-effects.

"We will have plenty of time to see how things work out there. If within the first three months its usage in the UK is stimulating with less documented side-effects, it may encourage our confidence in using it as well," he said during his press conference.

Precisely if you guys got news whether good or bad news, I would appreciate it very much. It actually help me in my investment. But please make sure the news is credible with links. Rumors / Hints or "you think la" are not welcomed. And don't tell me your friend told you this and that. TQ Guys.

You just bought a beautiful car, then someone came to your house to condemn this car. Not good la, No power la. Maint. very expensive, the other car is much better...so what do you do? Sell the car or keep the car? Or say how you enjoy your car? My car or your car?

Big difference between professionals and politicians

@angelo, noted. tks

China likely to approve a COVID-19 vaccine by year end to meet the need of epidemic-stricken countries: experts
https://www.globaltimes.cn/content/1207968.shtml

www.krbamboo.com

This tweet?
Good analysis on Malaysia’s vaccine procurement strategy. Especially, this paragraph. Certain middlemen peddling misinformation. That’s why, at the end of the day, NPRA will decide as
@DGHisham said.

https://twitter.com/Khairykj/status/1333251122966872064

Interesting read..

https://www.cnbc.com/2020/11/30/covid-china-vaccines-have-an-appeal-in-developing-countries.html

Kanger not interested in goreng. If want goreng pisang, ubi, kentang..this place not for you.

@eyehunter..dah berapa kali told you this is for long term counter. If no patience..shhhh....don't disturb. Want easy money, go find others.

No knee jerk...still steady

Kanger International Bhd (0170)
• KANGER dropped 2.7% or 0.5 sen to RM0.18 yesterday.
• Chart-wise, share price has been in consolidation mode for some time with trading volume
improving of late showing signs of stealth buying pattern. News of the company signing
collaboration agreement Sinopharm to distribute Covid-19 vaccine and has received support from
Ministry of Science, Technology and Innovation is likely to spur buying interest as one of the potential
vaccine-play stocks.
• From here, resistance levels are expected at RM0.195 (R1) and RM0.230 (R2) level.
• On the downside, support levels are set at RM0.160 (S1) and RM0.120 (S2).

Sinopharm had indicated earlier that they will only release its clinical trial data only after approval from Chinese Health authorities. If Noor Hisham's news is used as basis, that means approval of Sinopharm is imminent next week. I hope I am right.

I believe it will be from Sinopharm as they had already submitted for registration with China Health regulators.
It cannot be Pfizer as their meeting with FDA is on 10/12 and details cannot be revealed until then. Astrazeneca is going trough retrial. Cansino is due only in 2022. Sinovac a bit quiet on their registration.
-----------------------------------------------------------------------------------------------------------------------------------

KUALA LUMPUR: The Health Ministry is expected to receive data on phase three of the Covid-19 vaccine clinical trial from one of 10 companies it is negotiating with.

Health director-general Tan Sri Dr Noor Hisham Abdullah said the report "will most likely" be ready next week, but stressed that the vaccine will only get a green light if the company is able to acquire a licence.

"After receiving (the report), we will study it. (Later), the vaccine will be brought to the National Pharmaceutical Regulatory Agency (NPRA) and the Food and Drug Administration (FDA) for their approvals.

"If the vaccine is neither approved nor licensed, it means it can't be sold like other medicines in the country.

https://www.msn.com/en-my/news/national/dr-noor-hisham-msia-to-receive-covid-19-vaccine-clinical-trial-data-next-week/ar-BB1butPW

Frankly, I see no problems in the qr. I have seen worse ones. Most importantly in any recession or in this case pandemic, there must be an ongoing business and with low overheads and strong cash flow to pull through. In fact, I am going to load more if the price falls below my average price.

Rolling out to buy low to collect more if it goes down. I am here to stay.

I only see they have RM32m cash with another RM90m in receivables against bank borrowings of RM18m and payables of RM29m. That's all I need to know. Company make money or lose money is not as important as cash flow.

This qr is as at 30/9/20 la.

@angelo, what you think of the accounts?

https://www.cnbc.com/amp/2020/11/30/covid-china-vaccines-have-an-appeal-in-developing-countries.html

@jasonred, what you are saying now about warning is totally not what you posted earlier. No relevance.

"When Sinopharm gets approval, most of the marketting and distribution rights for Malaysia will go to GI Healthcare. Kanger only signed with Sinopharm Medical Hunan Changde.
30/11/2020 12:55 PM"

Anyway, TQ for your concern and warning.

@jasonred, tq for being up front. Just to let you know I did not go to the extent of asking my lawyers but I have a copy of SSM search on GI Resources. So no need to go into details. Of course I would not invest without knowing a little bit about the company.

Maybe you did not know, Kanger China is actually a 70:30 Private Public JV with local Government in Jingzhou Hunan, so not surprising they can sign an agreement with Sinopharm Hunan as well. In corporate world especially in a state owned company involving such high profile vaccine, it is impossible to ignore whatever agreements especially when it involve its subsidiaries. It may not be in the know then but once it is made known, agreements must be honored. That's how business operate.

Enjoy the process of investment. If it gives you discomfort or stress, then it is better not to get involved. many good counters out there for you to pick. I would be happy to hear more contributions from you in future but please be prepared to substantiate your arguments. Good luck.

To my fellow Kanger investors, pls excuse this noobie ranting. Hahahaha...

PM dept Budget approved.

@angelo, TQ for your analysis. We always try our best in our investments.

On 2nd thoughts, No one will do any business with a shell company. You need setup, operations, experience, credibility and distribution network. We are talking about medical care with no time to spare. Having lots money and powerful people is just not good enough.

@jasonred, My thoughts would be Kanger investors are more into the on going business of the company ie world largest processor of bamboo products for floor and furniture, sand export from Malaysia and antibacterial castings.
Vaccine would be a short term contract, more like a bonus business opportunity. The first vaccine to be approved would make most money, the last one to be approved would be left holding the crying baby. It applies to every vaccine counter from Bintai to HWGB, etc.
Long term investors would talk about ongoing business, short term investors would be looking only at vaccine. My 2 sen worth. I believe you are a short term investor. Nothing wrong with that, it is absolutely alright to look for quick profits in share market.

@jasonred, and what do you think of the letter Mosti gave to Kanger?

Please share information..don't keep all to yourself.

@jasonred79, do you know how big is GI Healthcare and their operations? Sounds like very big company.

@NPRA, IMBCAMS is doing trial in Malaysia with KKM about 3000 tests. Any idea their vaccine is based on as I read they had so many versions.

@purple.if you do the research how Bintai came in few months ago from 10 sen to what's today and what was their background, how they sign agreements after agreements projecting who they are..you will find your answer.

2022?

Not good day

All vaccine counters huat huat

Rising tide lift all boats.

@huatkopi, It is for Emergency Use Authorisation...not general use. Still need to wait.

Yes, Sinopharm / CNBG as it is state owned.

Interesting question: China Government said to give priority vaccine to Malaysia. Which of the 3 companies do you think China will ask to help Mslaysia?

Not yet approved how to fly?